Macrogenics inc (MGNX)
| eröffnet am: | 23.04.17 20:51 von: | Chalifmann3 |
| neuester Beitrag: | 12.09.23 16:02 von: | Saramee |
| Anzahl Beiträge: | 100 | |
| Leser gesamt: | 28188 | |
| davon Heute: | 1 | |
bewertet mit 2 Sternen |
||
|
|
||
74 Postings ausgeblendet.
07.09.22 16:43
#79
Balu4u
Ja, für mich aktuell kein Kauf
da muss erst das Cash-Problem gelöst werden. Auch wenn die Kursziele hier verlockend sind. Bringt dies ohne Cash gar nichts
https://www.nasdaq.com/articles/...will-have-to-spend-its-cash-wisely
https://www.nasdaq.com/articles/...will-have-to-spend-its-cash-wisely
17.10.22 14:14
#80
Saramee
Gilead und Macrogenics
Eine interessante News:
https://www.gilead.com/news-and-press/press-room/...ecific-antibodies
Gilead and MacroGenics Announce Oncology Collaboration to Develop Bispecific Antibodies
– Gilead Granted Exclusive Option to License MGD024, a Phase 1 CD123×CD3 DART® Molecule with Potential to Treat Various Hematologic Malignancies –
– Potential for Companies to Collaborate on Two Additional Future Research Programs –
FOSTER CITY, Calif. & ROCKVILLE, Md.--(BUSINESS WIRE)-- Gilead Sciences, Inc. (NASDAQ: GILD) and MacroGenics (NASDAQ: MGNX) today announced an exclusive option and collaboration agreement to develop MGD024, an investigational, bispecific antibody that binds CD123 and CD3 using MacroGenics’ DART® platform, and two additional bispecific research programs. The collaboration agreement grants Gilead the option to license MGD024, a potential treatment for certain blood cancers, including acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS).
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20221016005052/en/
A leader in the bispecific antibody space, MacroGenics has extensive experience applying its proprietary DART platform to develop novel therapeutics. MGD024 is a next-generation, bispecific that incorporates a CD3 component that is designed to minimize cytokine-release syndrome (CRS), a potentially life-threatening toxicity, while increasing the magnitude of antitumor activity with a longer half-life to permit intermittent dosing.
“MacroGenics’ bispecific expertise naturally complements Gilead’s portfolio strengths in immuno-oncology and our growing hematology franchise,” said Bill Grossman, MD, PhD, Senior Vice President, Oncology Clinical Development, Gilead Sciences. “We believe MGD024, with its potential to reduce CRS and permit intermittent dosing through a longer half-life, could translate to more patient-friendly dosing and enhanced clinical outcomes for people living with AML and MDS. This partnership is the latest in our efforts to develop and advance transformative new cancer therapies as we deepen our portfolio across oncology indications.”
Scott Koenig, MD, PhD, President, and CEO, MacroGenics said, “Rapid advances over the last decade have made CD123 a very promising target in oncology research. Advancing our bispecific DART molecule, MGD024, through a strategic collaboration with the team at Gilead will accelerate our ability to drive further development of MGD024 to the potential benefit of people living with blood cancers.”
MacroGenics will be responsible for the ongoing Phase 1 study for MGD024 during which Gilead may elect to exercise its option to license the program at predefined decision points. The Phase 1 study will include a dose escalation segment and an expansion segment that is intended to evaluate MGD024 as monotherapy and in combination with other therapies across multiple indications.
Financial Considerations
As part of the agreement, Gilead will pay MacroGenics an upfront payment of $60 million and MacroGenics will be eligible to receive up to $1.7 billion in target nomination, option fees, and development, regulatory and commercial milestones. MacroGenics will also be eligible to receive tiered, double-digit royalties on worldwide net sales of MGD024 and a flat royalty on worldwide net sales of products under the two research programs.
Beginning in the first quarter of 2022, consistent with recent industry communications from the U.S. Securities and Exchange Commission (SEC), Gilead no longer excludes acquired IPR&D expenses from its non-GAAP financial measures and expects the transaction with MacroGenics to reduce Gilead’s GAAP and non-GAAP 2022 EPS by approximately $0.04.
https://www.gilead.com/news-and-press/press-room/...ecific-antibodies
Gilead and MacroGenics Announce Oncology Collaboration to Develop Bispecific Antibodies
– Gilead Granted Exclusive Option to License MGD024, a Phase 1 CD123×CD3 DART® Molecule with Potential to Treat Various Hematologic Malignancies –
– Potential for Companies to Collaborate on Two Additional Future Research Programs –
FOSTER CITY, Calif. & ROCKVILLE, Md.--(BUSINESS WIRE)-- Gilead Sciences, Inc. (NASDAQ: GILD) and MacroGenics (NASDAQ: MGNX) today announced an exclusive option and collaboration agreement to develop MGD024, an investigational, bispecific antibody that binds CD123 and CD3 using MacroGenics’ DART® platform, and two additional bispecific research programs. The collaboration agreement grants Gilead the option to license MGD024, a potential treatment for certain blood cancers, including acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS).
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20221016005052/en/
A leader in the bispecific antibody space, MacroGenics has extensive experience applying its proprietary DART platform to develop novel therapeutics. MGD024 is a next-generation, bispecific that incorporates a CD3 component that is designed to minimize cytokine-release syndrome (CRS), a potentially life-threatening toxicity, while increasing the magnitude of antitumor activity with a longer half-life to permit intermittent dosing.
“MacroGenics’ bispecific expertise naturally complements Gilead’s portfolio strengths in immuno-oncology and our growing hematology franchise,” said Bill Grossman, MD, PhD, Senior Vice President, Oncology Clinical Development, Gilead Sciences. “We believe MGD024, with its potential to reduce CRS and permit intermittent dosing through a longer half-life, could translate to more patient-friendly dosing and enhanced clinical outcomes for people living with AML and MDS. This partnership is the latest in our efforts to develop and advance transformative new cancer therapies as we deepen our portfolio across oncology indications.”
Scott Koenig, MD, PhD, President, and CEO, MacroGenics said, “Rapid advances over the last decade have made CD123 a very promising target in oncology research. Advancing our bispecific DART molecule, MGD024, through a strategic collaboration with the team at Gilead will accelerate our ability to drive further development of MGD024 to the potential benefit of people living with blood cancers.”
MacroGenics will be responsible for the ongoing Phase 1 study for MGD024 during which Gilead may elect to exercise its option to license the program at predefined decision points. The Phase 1 study will include a dose escalation segment and an expansion segment that is intended to evaluate MGD024 as monotherapy and in combination with other therapies across multiple indications.
Financial Considerations
As part of the agreement, Gilead will pay MacroGenics an upfront payment of $60 million and MacroGenics will be eligible to receive up to $1.7 billion in target nomination, option fees, and development, regulatory and commercial milestones. MacroGenics will also be eligible to receive tiered, double-digit royalties on worldwide net sales of MGD024 and a flat royalty on worldwide net sales of products under the two research programs.
Beginning in the first quarter of 2022, consistent with recent industry communications from the U.S. Securities and Exchange Commission (SEC), Gilead no longer excludes acquired IPR&D expenses from its non-GAAP financial measures and expects the transaction with MacroGenics to reduce Gilead’s GAAP and non-GAAP 2022 EPS by approximately $0.04.
17.10.22 16:41
#81
Vassago
MGNX 3.41$
Kollaboration mit Gilead
- Gilead erhält exklusive Option zur Lizenzierung von MGD024, einem Phase-1-CD123×CD3-DART®-Molekül mit Potenzial zur Behandlung verschiedener hämatologischer Malignome
- Potenzial für Unternehmen zur Zusammenarbeit bei zwei weiteren zukünftigen Forschungsprogrammen
- 60 Mio. $ als Vorabzahlung
- bis zu 1,7 Mrd. $ in Meilensteinzahlungen
http://ir.macrogenics.com/news-releases/...logy-collaboration-develop
23.10.22 09:52
#82
Vassago
MGNX 4.80$ (+19%)
BB Biotech stockt auf
- am 19/10/22 wurden 168.422 Aktien zu je 3,7045$ gekauft
- am 20/10/22 wurden 285.977 Aktien zu je 3,9988$ gekauft
- Volumen der beiden Transaktionen 1,77 Mio. $
https://app.quotemedia.com/data/...ateFiled=2022-10-21&CK=1125345
29.12.22 19:28
#84
Vassago
MGNX 6.43$ (+13%)
BB Biotech kauft wieder nach
- am 23/12/22 wurden 200.000 Aktien zu je 5,884$ gekauft
- am 27/12/22 wurden 200.000 Aktien zu je 5,609$ gekauft
https://www.sec.gov/Archives/edgar/data/1259870/...slF345X03/doc4.xml
17.02.23 21:13
#86
Saramee
ASCO-Genitourinary Cancers Symposium 2023 Conferen
findet vom Feb 16 - Feb 18, 2023 statt:
http://ir.macrogenics.com/events-and-presentations/events
Vielleicht ist es das.
Ansonsten gab es diese Neuigkeit:
http://ir.macrogenics.com/news-releases/...linical-results-single-arm
MacroGenics Announces Preliminary Clinical Results from Single Arm Study of Lorigerlimab in Patients with Metastatic Castration-Resistant Prostate Cancer to be Presented at ASCO Genitourinary Cancers Symposium
http://ir.macrogenics.com/events-and-presentations/events
Vielleicht ist es das.
Ansonsten gab es diese Neuigkeit:
http://ir.macrogenics.com/news-releases/...linical-results-single-arm
MacroGenics Announces Preliminary Clinical Results from Single Arm Study of Lorigerlimab in Patients with Metastatic Castration-Resistant Prostate Cancer to be Presented at ASCO Genitourinary Cancers Symposium
18.02.23 12:56
#88
Saramee
BB Biotech
...hält nach eigenen Angaben 14,5% an der Firma:
https://www.bbbiotech.ch/ch-de/private/...ere-investments/macrogenics
https://www.bbbiotech.ch/ch-de/private/...ere-investments/macrogenics
16.03.23 17:06
#89
Saramee
Gestern
...gab es die Berichte von 2022:
http://ir.macrogenics.com/news-releases/...and-2022-financial-results
Und heute geht die Aktie schön nach oben.
http://ir.macrogenics.com/news-releases/...and-2022-financial-results
Und heute geht die Aktie schön nach oben.
16.03.23 20:00
#90
Balu4u
Cash bis 2025
Cash Runway Guidance: MacroGenics anticipates that its cash, cash equivalents and marketable securities balance of $154.3 million as of December 31, 2022, plus the $100 million proceeds received from DRI related to the sale of the Companys TZIELD royalty interest, projected and anticipated future payments from partners and product revenues should extend its cash runway through 2025. The Companys expected funding requirements reflect anticipated expenditures related to the Phase 2 TAMARACK clinical trial, the planned Phase 2 study of lorigerlimab in mCRPC as well as MacroGenics other clinical and preclinical studies currently ongoing.
23.03.23 13:38
#91
Vassago
MGNX 7.00$
15 Mio. $ Meilensteinzahlung von Incyte
http://ir.macrogenics.com/news-releases/...-following-us-fda-approval
05.06.23 20:27
#93
Balu4u
Geht es wieder hoch?
https://www.nasdaq.com/market-activity/stocks/mgnx/real-time
26.07.23 18:01
#94
Vassago
MGNX 4.64$
Zahlen für Q1/23
- Umsatz 24 Mio. $
- Verlust 38 Mio. $
- Cash 242 Mio. $
- MK 287 Mio. $
- Cash runway through 2025
http://ir.macrogenics.com/news-releases/...orate-progress-and-first-6
10.08.23 16:40
#95
Saramee
Gute Nachrichten
... finden sich hier:
https://www.finanznachrichten.de/...er-2023-financial-results-399.htm
https://www.finanznachrichten.de/...er-2023-financial-results-399.htm
10.08.23 19:05
#96
Balu4u
Es geht aber nicht wegen den Zahlen hoch...
https://www.nasdaq.com/articles/...f-macrogenics-are-jumping-thursday
10.08.23 19:08
#97
Balu4u
Cashreichweite wurde also bis 2026 verlängert
wegen den Meilensteinzahlungen von Sanofi
The company has only one commercial product of its own, breast cancer treatment Margenza. However, it receives royalties and milestone payments for Tzield and if that drug adds indications, MacroGenics will benefit. The company has also strengthened its cash position to $240 million, not counting the payment from Sanofi, compared to $154.3 million at the beginning of the year.
The extra funds should help support operations through 2026, the company said. That means MacroGenics has enough to fund its phase 2 trials for lorigerlimab and vobramitamab duocarmazine.
The company has only one commercial product of its own, breast cancer treatment Margenza. However, it receives royalties and milestone payments for Tzield and if that drug adds indications, MacroGenics will benefit. The company has also strengthened its cash position to $240 million, not counting the payment from Sanofi, compared to $154.3 million at the beginning of the year.
The extra funds should help support operations through 2026, the company said. That means MacroGenics has enough to fund its phase 2 trials for lorigerlimab and vobramitamab duocarmazine.
11.08.23 15:49
#98
Balu4u
Geht`s heute weiter?
https://www.nasdaq.com/de/market-activity/stocks/mgnx/real-time
12.09.23 16:02
#100
Saramee
MacroGenics Announces Achievement of $15 Million M
MacroGenics, Inc. (NASDAQ: MGNX), ein biopharmazeutisches Unternehmen, das sich auf die Entwicklung, Herstellung und Vermarktung innovativer antikörperbasierter Therapeutika zur Behandlung von Krebs konzentriert, gab heute bekannt, dass sein Partner Gilead Sciences, Inc. (NASDAQ: GILD) das Unternehmen nominiert hat erstes von zwei Forschungsprogrammen, die die DART®- und TRIDENT®-Plattformen von MacroGenics zur Erzeugung bispezifischer Antikörper nutzen. Diese Nominierung gewährt Gilead bei Erreichen eines vorab festgelegten präklinischen Meilensteins die exklusive Option, weltweite Rechte am Forschungsprogramm zu lizenzieren.
Im Rahmen der Vereinbarung vom Oktober 2022 erhält MacroGenics (MGNX) 15 Millionen US-Dollar im Zusammenhang mit der Nominierung eines bispezifischen Forschungsprogramms, das von MacroGenics durchgeführt und von Gilead finanziert wird. Gemäß dieser Vereinbarung, die MGD024, einen in der Erprobung befindlichen bispezifischen Antikörper, der mithilfe der DART-Plattform von MacroGenics CD123 und CD3 bindet, sowie bis zu zwei weitere bispezifische Forschungsprogramme abdeckt, bleibt MacroGenics berechtigt, bis zu 1,7 Milliarden US-Dollar an Zielnominierungen, Optionsgebühren und und Entwicklungs-, Regulierungs- und kommerzielle Meilensteine. MacroGenics hat außerdem Anspruch auf gestaffelte zweistellige Lizenzgebühren auf weltweite Nettoverkäufe von MGD024 und eine Pauschallizenzgebühr auf weltweite Nettoverkäufe von Produkten im Rahmen der beiden Forschungsprogramme.
https://seekingalpha.com/pr/...mination-of?hasComeFromMpArticle=false
Im Rahmen der Vereinbarung vom Oktober 2022 erhält MacroGenics (MGNX) 15 Millionen US-Dollar im Zusammenhang mit der Nominierung eines bispezifischen Forschungsprogramms, das von MacroGenics durchgeführt und von Gilead finanziert wird. Gemäß dieser Vereinbarung, die MGD024, einen in der Erprobung befindlichen bispezifischen Antikörper, der mithilfe der DART-Plattform von MacroGenics CD123 und CD3 bindet, sowie bis zu zwei weitere bispezifische Forschungsprogramme abdeckt, bleibt MacroGenics berechtigt, bis zu 1,7 Milliarden US-Dollar an Zielnominierungen, Optionsgebühren und und Entwicklungs-, Regulierungs- und kommerzielle Meilensteine. MacroGenics hat außerdem Anspruch auf gestaffelte zweistellige Lizenzgebühren auf weltweite Nettoverkäufe von MGD024 und eine Pauschallizenzgebühr auf weltweite Nettoverkäufe von Produkten im Rahmen der beiden Forschungsprogramme.
https://seekingalpha.com/pr/...mination-of?hasComeFromMpArticle=false